Movatterモバイル変換

[0]ホーム
URL:

Zhu et al., 2024 - Google Patents

HA/PLA Composite Nanoparticles for Enhanced Oral Bioavailability of Capsaicin: Fabrication, Characterization and in vitro‐in vivo Evaluation

Zhu et al., 2024

Document ID
14906525032661232482
Author
Zhu Y
Wang H
Adu‐Frimpong M
Zou Z
Jin Z
Zhang P
Xue Y
Li S
Xu Y
Yu J
Xu X
Publication year
Publication venue
ChemistrySelect

External Links

Snippet

In this paper, hydroxylapatite (HA) nanoparticles were constructed through the ultrasound‐ assisted dispersion method. Using scanning electron microscopy (SEM), we studied the preparation methods of HA nanoparticles, and spherical HA nanoparticles with a size of …
Continue reading atchemistry-europe.onlinelibrary.wiley.com (other versions)

Classifications

The classifications are assigned by a computer and are not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin

Similar Documents

PublicationPublication DateTitle
Nanda et al.Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel
CA2338031C (en)Biodegradable compositions for the controlled release of encapsulated substances
Siafaka et al.Synthesis of folate-pegylated polyester nanoparticles encapsulating ixabepilone for targeting folate receptor overexpressing breast cancer cells
Tan et al.Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems
Yan et al.Stable and biocompatible cellulose-based CaCO3 microspheres for tunable pH-responsive drug delivery
Wang et al.Electrosprayed soft capsules of millimeter size for specifically delivering fish oil/nutrients to the stomach and intestines
CN103330680A (en)Nano drug transdermal preparation and preparation method thereof
Liu et al.Preparation and characterization of paclitaxel/chitosan nanosuspensions for drug delivery system and cytotoxicity evaluation in vitro
Guo et al.A GO@ PLA@ HA composite microcapsule: Its preparation and multistage and controlled drug release
Shende et al.Polymeric nanodroplets: an emerging trend in gaseous delivery system
Dash et al.Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate (AT-CU) nanoparticles, overcoming the barriers associated with PLGA: An approach for better management of atherosclerosis
CN107412196B (en)Orlistat nanoparticle and preparation method thereof and the application in antitumor drug
Nie et al.Preparation and characterization of sodium alginate/phosphate-stabilized amorphous calcium carbonate nanocarriers and their application in the release of curcumin
Dubnika et al.Development of vancomycin delivery systems based on autologous 3D platelet-rich fibrin matrices for bone tissue engineering
Li et al.Urchin-like hydroxyapatite/graphene hollow microspheres as pH-responsive bone drug carriers
Guo et al.Thermosensitive hydrogel drug delivery system containing doxorubicin loaded CS–GO nanocarriers for controlled release drug in situ
Yuan et al.Using co-axial electrospray deposition to eliminate burst release of simvastatin from microparticles and to enhance induced osteogenesis
Zhu et al.HA/PLA Composite Nanoparticles for Enhanced Oral Bioavailability of Capsaicin: Fabrication, Characterization and in vitro‐in vivo Evaluation
CN103585113B (en)Apigenin polylactic acid sustained release microsphere and preparation method thereof
López et al.Physicochemical characterization of functionalized-nanostructured-titania as a carrier of copper complexes for cancer treatment
Li et al.pH-responsive degradable mesoporous organosilica nanoparticle for tumor targeting and phototherapy combined with chemotherapy
CN1299685C (en)Fluorouracil medicine carrier microsphere and production thereof
Rimsueb et al.Feeding cells with a novel “trojan” carrier: citrate nanoparticles
CN100344277C (en)Nano-magnetic medicinal microglobule, its preparation method and application
CN118806724A (en) Drug delivery carrier for inhibiting glycogen release and treating large liposarcoma and preparation method thereof
[8]ページ先頭
©2009-2025 Movatter.jp